Research programme: trastuzumab-drug conjugate - Alteogen/3SBio

Drug Profile

Research programme: trastuzumab-drug conjugate - Alteogen/3SBio

Alternative Names: ALT-P7; HM2-drug conjugate; HM2-MMAE; Trastuzumab-drug conjugate - Alteogen/3SBio

Latest Information Update: 19 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alteogen
  • Class Antineoplastics; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 18 Sep 2017 Alteogen plans a phase I trial for Breast cancer (Second-line therapy or greater, Metastatic disease) (IV) in October 2017 (NCT03281824)
  • 11 Oct 2015 Preclinical trials in Breast cancer in South Korea (IV) prior to October 2015
  • 11 Oct 2015 3SBio plans clinical trials for Breast cancer in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top